Bicocca Open Archive

Logo unimib boa
SINICO, RENATO ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.946
EU - Europa 6.510
AS - Asia 3.130
SA - Sud America 46
Continente sconosciuto - Info sul continente non disponibili 32
OC - Oceania 17
AF - Africa 16
Totale 27.697
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.530
IT - Italia 1.355
IE - Irlanda 1.292
CN - Cina 1.155
SG - Singapore 948
RU - Federazione Russa 882
SE - Svezia 861
DE - Germania 630
HK - Hong Kong 525
GB - Regno Unito 395
CA - Canada 392
UA - Ucraina 307
FI - Finlandia 249
TR - Turchia 241
AT - Austria 183
FR - Francia 172
VN - Vietnam 79
DK - Danimarca 61
JP - Giappone 56
IN - India 45
EU - Europa 30
NL - Olanda 25
ES - Italia 21
KR - Corea 21
MX - Messico 20
BE - Belgio 19
AU - Australia 15
CL - Cile 14
RO - Romania 14
ID - Indonesia 13
IL - Israele 12
BR - Brasile 10
CO - Colombia 9
CZ - Repubblica Ceca 9
CH - Svizzera 8
IR - Iran 7
PE - Perù 6
SA - Arabia Saudita 6
BG - Bulgaria 5
EG - Egitto 5
PT - Portogallo 5
EC - Ecuador 4
NO - Norvegia 4
AE - Emirati Arabi Uniti 3
AR - Argentina 3
GR - Grecia 3
HU - Ungheria 3
PK - Pakistan 3
PL - Polonia 3
SC - Seychelles 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
IQ - Iraq 2
KZ - Kazakistan 2
LB - Libano 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
TN - Tunisia 2
AM - Armenia 1
BD - Bangladesh 1
CR - Costa Rica 1
DM - Dominica 1
DZ - Algeria 1
ET - Etiopia 1
HN - Honduras 1
IS - Islanda 1
KE - Kenya 1
KH - Cambogia 1
LI - Liechtenstein 1
MA - Marocco 1
MD - Moldavia 1
MN - Mongolia 1
MY - Malesia 1
NI - Nicaragua 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 27.697
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.897
Woodbridge 2.065
Chandler 1.378
Dublin 1.230
Houston 1.224
Fairfield 1.043
Dearborn 832
Wilmington 790
Jacksonville 783
Singapore 757
Ashburn 713
Princeton 540
Hong Kong 513
New York 509
Frankfurt am Main 482
Seattle 407
Cambridge 360
Milan 347
Nanjing 253
Lawrence 243
Altamura 211
Lachine 195
Vienna 182
Boardman 169
Beijing 141
Santa Clara 135
Lissone 123
Shanghai 115
San Diego 110
Ottawa 101
Andover 83
Nanchang 76
Shenyang 70
Toronto 65
Guangzhou 61
Hebei 60
Norwalk 59
Falls Church 53
Jiaxing 42
London 39
Los Angeles 39
Washington 39
Changsha 38
Helsinki 38
Tianjin 38
Chicago 36
Mountain View 36
Dong Ket 33
Jinan 33
Hefei 24
Redmond 24
Zhengzhou 24
Hangzhou 22
Rome 22
Philadelphia 20
Kunming 19
Pune 19
Brussels 17
Florence 16
Kocaeli 16
Tokyo 16
Fremont 14
Lappeenranta 14
Turin 14
Tappahannock 13
Edmonton 12
Gwangmyeong 12
Jakarta 12
Sacramento 12
San Mateo 12
Brescia 11
Kilburn 11
Auburn Hills 10
Munich 10
Phoenix 10
Taizhou 10
Wuhan 10
Caronno Pertusella 9
Detroit 9
Palermo 9
Brno 8
Paris 8
Santa Monica 8
Verona 8
Dallas 7
Genoa 7
Hounslow 7
Melbourne 7
Olbia 7
Padova 7
Paullo 7
San Francisco 7
Siena 7
Tel Aviv 7
Berlin 6
Fuzhou 6
Genova 6
Hanoi 6
Kiev 6
Melzo 6
Totale 21.377
Salva come PNG Salva come JPEG
Nome #
Modifications in peripheral-blood lymphocyte subpopulations induced by plasmapheresis and immunosuppressive drugs 385
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 319
Combined Plasmatic and Tissue Approach to Membranous Nephropathy-Proposal of a Diagnostic Algorithm Including Immunogold Labelling: Changing the Paradigm of a Serum-based Approach 305
MALDI imaging in Fabry nephropathy: a multicenter study 294
MALDI-MSI Approach to Renal Biopsies of Patients with Fabry Disease 261
MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy 261
Microscopic Polyangiitis 258
Kidney Involvement 232
Rituximab as maintenance treatment for systemic Lupus ErythematosusA multicentre observational study of 147 patients 232
135. ATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS 220
Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases 219
Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient) 212
117. Prediction of Long-Term Evolutionary Profiles in Eosinophilic Granulomatosis with Polyangiitis (Churg– Strauss) Based on Baseline and Follow-Up Characteristics 196
162. Cluster analysis to explore clinical subclassification of eosinophilic granulomatosis with polyangiitis (churg–strauss) 188
Renal involvement in Churg-Strauss syndrome 186
Neutrophil Extracellular Traps (NETs) profiles in patients with incident SLE and lupus nephritis 185
HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome 182
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy 182
Lack of IgA antineutrophil cytoplasmic antibodies in Henoch-Schönlein purpura and IgA nephropathy 181
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis 180
Aberrant N-glycosylation patterns related to serum IgG subclasses in Idiopathic membranous nephropathy 179
Systemic Vasculitis and Pregnancy: A Multicenter Study on Maternal and Neonatal Outcome of 66 Prospectively Followed Pregnancies 168
Systemic Vasculitis and Pregnancy: a Multicenter Study On Maternal and Neonatal Outcome of 43 Prospectively Followed Pregnancies 165
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status 161
Anti-Neutrophil Cytoplasmic Antibodies Positivity and Anti-Leukotrienes in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Monocentric Study on 134 Italian Patients 160
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 157
Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN) 155
Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 155
Sneddon's syndrome: clinical and immunohistochemical findings 154
354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 154
Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): Planted antigens 152
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis 150
[OP.4B.05] MIR-30A-3P EXPRESSION IN THE HEARTS OF DIABETIC RATS 148
RITUXIMAB AS MAINTENANCE THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS 147
255. Renal involvement in EGPA: a multicentre retrospective study of 63 cases 147
Multiple hepatic abscesses complicating continuous ambulatory peritoneal dialysis 144
Lymphocyte populations in the peripheral blood from patients with IgA nephropathy 143
Neutrophil Extracellular Traps in the Autoimmunity Context 143
Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study 142
Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain 142
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis 141
The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy 140
Eosinophilic granulomatosis with polyangiitis (churg-straus syndrome) 140
Anticoagulant-related nephropathy: a pathological note 136
FP165 Slowly progressive anca-associated glomerulonephritis: a multicentre study 134
Immunology of membranous nephropathy: From animal models to humans 133
Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases 131
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients 131
Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study 131
Role and clinical significance of rheumatoid factors in glomerulonephritis 130
Polymeric IgA rheumatoid factor in idiopathic IgA mesangial nephropathy (Berger's disease) 129
ANCA-associated vasculitis in childhood: Recent advances 129
Outcome of Different Induction Regimens in Anca-Associated Glomerulonephritis According to the Histopathological Characteristics: the Reassess Study* 129
Clinical evaluation of a rapid immunofluorescence test (IIFT) for diagnosis of ANCA-associated vasculitis 128
Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 127
Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis [Position paper] 127
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 127
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 126
Plasma-exchange and glomerulonephritis 125
Characterization of anti-myeloperoxidase antibodies in vasculitis 125
ANCA with specificity for lactoferrin in systemic lupus erythematosus (SLE) 125
alpha 1-Antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis: genetic and clinical implications 124
Clinical significance of autoantibodies to myeloperoxidase in vasculitic syndromes 124
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies 124
Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis 124
Plasma-exchange in immunologically mediated glomerular diseases 122
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 121
Specificity of anti-neutrophil cytoplasm antibodies (ANCA) in vasculitic syndromes 121
T-lymphocyte subsets in primary and secondary glomerulonephritis 120
Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: A comparison of different assays 119
Clinical significance of antineutrophil cytoplasmic autoantibodies with specificity for lactoferrin in renal diseases 118
Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis 117
Cluster analysis identifies distinct pathogenetic patterns in c3 glomerulopathies/immune complex–Mediated membranoproliferative GN 114
Spontaneous and pokeweed mitogen induced production of rheumatoid factor and immunoglobulins in type II essential mixed cryoglobulinaemia 114
Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity? 114
Destructuring glomerular diseases with structured deposits: challenges in the precision medicine era 114
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide 113
The subclavian vein as an emergency vascular access for hemodialysis and plasma exchange 113
Anti-C1q autoantibodies in lupus nephritis: Prevalence and clinical significance 112
B lymphocyte subpopulations and T-cell subsets in primary chronic glomerulonephritis 111
L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 111
Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome 111
Infectious serologies and autoantibodies in wegener's granulomatosis and other vasculitides: Novel associations disclosed using the rad BioPlex 2200 110
Anti-M-Type Phospholipase A2 Receptor (PLA2R) Antibodies: Diagnostic Performance and Clinical Significance in Idiopathic Membranous Nephropathy (IMN) 110
Effect of a continuous blood-cell separator and a polypropilene plasma filter on complement and platelet activation 110
ANCA-associated vasculitides (AAV) from the gender point of view 109
Renal vasculitis 108
FP216Renal involvement in EGPA : a multicentre retrospective study of 63 cases 108
Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis 107
Meningeal involvement in apparently ANCA-negative Wegener's granulomatosis: A role for PR3 capture-ELISA? [1] 106
Role of monocytes in extracapillary glomerulonephritis (gn) - histochemical-study in 15 patients 106
Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy 105
Immunoglobulin heavy chain switch region gene polymorphisms in glomerulonephritis 105
Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies 104
European consensus statement on the terminology used in the management of lupus glomerulonephritis 104
Detection of anti-IFI16 antibodies by ELISA: Clinical and serological associations in systemic sclerosis 104
The kaleidoscopic manifestations of systemic vasculitis 103
Defective t-suppressor activity in type-i membranoproliferative glomerulonephritis (mpgn-i) 103
Anti-neutrophil cytoplasmic autoantibodies: Methodological aspects and clinical significance in systemic vasculitis 103
Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells 103
Totale 14.857
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.279
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.279
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.783 0 0 0 233 369 595 508 230 216 145 365 122
2020/20213.779 118 120 469 425 235 388 519 375 381 294 184 271
2021/20222.909 153 295 405 193 210 197 143 152 134 167 311 549
2022/20234.857 662 1.283 345 373 420 819 48 227 410 40 146 84
2023/20243.713 127 127 134 146 526 951 762 94 328 59 58 401
2024/20251.948 483 899 322 244 0 0 0 0 0 0 0 0
Totale 29.004